The advent of novel targeted therapies, including B-cell receptor (BCR) pathway and B-cell lymphoma 2 (BCL2) inhibitors, has substantially changed the treatment paradigm for chronic lymphocytic leukemia (CLL). Although targeted therapies have improved outcomes compared to traditional chemoimmunotherapy in the front-line and relapsed or refractory settings, they are associated with resistance mutations and suboptimal outcomes in certain high-risk patients. Additionally, targeted therapies are associated with drug interactions and unique adverse effect profiles which can be challenging for patients and clinicians to manage. Ongoing studies continue to address questions regarding optimal sequencing of therapies, the role of treatment combinations, and the efficacy of next-generation novel agents. This review provides a comprehensive overview regarding the clinical management of targeted therapies for CLL and applies current literature to clinical practice.
GaykoUFungMClowF, et al.Development of the Bruton's Tyrosine kinase inhibitor ibrutinib for B cell malignancies. Ann N Y Acad Sci2015; 1358: 82–94.
2.
BurgerJAGhiaPRosenwaldA, et al.The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood2009; 114: 3367–3375.
3.
MunirTBrownJRO’BrienS, et al.Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol2019; 94: 1353–1363.
PatelVBalakrishnanKBibikovaE, et al.Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells. Clin Cancer Res2017; 23: 3734–3743.
11.
Pal SinghSDammeijerFHendriksRW. Role of Bruton's Tyrosine kinase in B cells and malignancies. Mol Cancer2018; 17. doi:10.1186/s12943-018-0779-z
12.
ChengSMaJGuoA, et al.BTK Inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia2014; 28: 649–657.
13.
BrownJRRobakTGhiaP, et al.Efficacy and safety of Zanubrutinib in patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): follow-up results from arm C of the SEQUOIA (BGB-3111-304) trial. Blood2020; 136: 11–12.
14.
GuDTangHWuJ, et al.Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. J Hematol Oncol2021; 14. doi:10.1186/s13045-021-01049-7
15.
HonigbergLASmithAMSirisawadM, et al.The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A2010; 107: 13075–13080.
16.
GhasoubRAlbattahAElazzazyS, et al.Ibrutinib-associated sever skin toxicity: a case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia – case report and literature review. J Oncol Pharm Pract2020; 26: 487–491.
17.
ByrdJCFurmanRRCoutreSE, et al.Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med2013; 369: 32–42.
18.
ByrdJCBrownJRO’BrienS, et al.Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med2014; 371: 213–223.
19.
BurgerJATedeschiABarrPM, et al.Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med2015; 373: 2425–2437.
20.
BarrPMOwenCRobakT, et al.Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. J Clin Oncol2021; 39: 7523–7523.
21.
MorenoCGreilRDemirkanF, et al.Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol2019; 20: 43–56.
22.
WoyachJARuppertASHeeremaNA, et al.Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med2018; 379: 2517–2528.
23.
ShanafeltTDWang XVKayNE, et al.Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med2019; 381: 432–443.
24.
ShanafeltTDWangVKayNE, et al.Ibrutinib and rituximab provides superior clinical outcome compared to FCR in younger patients with chronic lymphocytic leukemia (CLL): extended follow-up from the E1912 trial. Blood2019; 134: 33–33.
25.
TamCSO’BrienSWierdaW, et al.Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood2008; 112: 975–980.
26.
FischerKBahloJFinkAM, et al.Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood2016; 127: 208–215.
27.
ZhouYTangGMedeirosLJ, et al.Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Mod Pathol2012; 25: 237–245.
28.
KutschNBahloJRobrechtS, et al.Long term follow-up data and health-related quality of life in frontline therapy of fit patients treated with FCR versus BR (CLL10 trial of the GCLLSG). HemaSphere2020; 4. doi:10.1097/HS9.0000000000000336
29.
BarfTCoveyTIzumiR, et al.Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther2017; 363: 240–252.
30.
ByrdJCHarringtonBO’BrienS, et al.Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med2016; 374: 323–332.
31.
GhiaPPlutaAWachM, et al.Ascend: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol2020; 38: 2849–2861.
32.
JurczakWPlutaAWachM, et al.Three-Year follow-up of the ascend trial: acalabrutinib vs rituximab Plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia. Blood2021; 138: 393–393.
33.
SharmanJPEgyedMJurczakW, et al.Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet2020; 395: 1278–1291.
34.
SharmanJPEgyedMJurczakW, et al.Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: elevate-TN four-year follow up. J Clin Oncol2021; 39: 7509–7509.
35.
ByrdJCHillmenPGhiaP, et al.Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol2021; 39: 3441–3452.
36.
TamCSTrotmanJOpatS, et al.Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood2019; 134: 851–859.
37.
HillmenPBrownJREichhorstBF, et al.ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Futur Oncol2020; 16: 517–523.
38.
HillmenPEichhorstBBrownJR, et al. First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma abstract LB1900. Presented at the 26th European Hematol. EHA Conf.Published online 2021.
39.
TamCSGiannopoulosKJurczakW, et al.SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Blood2021; 138: 396–396.
40.
TamCSRobakTGhiaP, et al.Efficacy and safety of zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with Del(17p): initial results from arm C of the Sequoia (BGB-3111-304) trial. Blood2019; 134: 499–499.
41.
GoedeVFischerKBuschR, et al.Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med2014; 370: 1101–1110.
42.
SharmanJPBranderDMMatoAR, et al.Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. Lancet Haematol2021; 8: e254–e266.
ZhouDPodollTXuY, et al.Evaluation of the drug–drug interaction potential of acalabrutinib and its active metabolite, ACP-5862, using a physiologically-based pharmacokinetic modeling approach. CPT Pharmacometrics Syst Pharmacol.2019; 8: 489–499.
45.
de JongJSkeeDMurphyJ, et al.Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. Pharmacol Res Perspect2015; 3. doi:10.1002/prp2.156
46.
de JongJHellemansPDe WildeS, et al.A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies. Leuk Lymphoma2018; 59: 2888–2895.
47.
MuSTangZNovotnyW, et al.Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's Tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects. Cancer Chemother Pharmacol2020; 85: 391–399.
48.
de ZwartLSnoeysJDe JongJ, et al.Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling. Clin Pharmacol Ther. Published online 2016:548–557. doi:10.1002/cpt.419
49.
SaadAHDePestelDDCarverPL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy2006; 26: 1730–1744.
50.
ZhangWLimLY. Effects of spice constituents on P-glycoprotein-mediated transport and CYP3A4-mediated metabolism in vitro. Drug Metab Dispos2008; 36: 1283–1290.
51.
FosterBCFosterMSVandenhoekS, et al.An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci2001; 4: 176–184.
52.
HellumBHNilsenOG. In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol2008; 102: 466–475.
53.
YamaoriSEbisawaJOkushimaY, et al.Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci2011; 88: 730–736.
54.
De JongJSukbuntherngJSkeeD, et al.The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol2015; 75: 907–916.
55.
SharmaSPepinXBurriH, et al.New acalabrutinib formulation enables co-administration with proton pump inhibitors and dosing in patients unable to swallow capsules (ELEVATE-PLUS). Blood2021; 138: 4365–4365.
DubovskyJABeckwithKANatarajanG, et al.Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood2013; 122: 2539–2549.
58.
MatoARNabhanCThompsonMC, et al.Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica2018; 103: 874–879.
59.
BarrPMBrownJRHillmenP, et al.Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood2017; 129: 2612–2615.
60.
ParikhSAAchenbachSJCallTG, et al.The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. Cancer Med2020; 9: 3390–3399.
61.
SteenmanMLandeG. Cardiac aging and heart disease in humans. Biophys Rev2017; 9: 131–137.
62.
ShanafeltTDParikhSANoseworthyPA, et al.Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma2017; 58: 1630–1639.
63.
TangCPSMcMullenJTamC. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. Leuk Lymphoma2018; 59: 1554–1564.
64.
O’BrienSHillmenPCoutreS, et al.Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma or mantle cell lymphoma. Clin Lymphoma. Myeloma Leuk2018; 18: 648–657, e15.
65.
TamCSOpatSD' et al.A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood2020; 136: 2038–2050.
66.
PretoriusLDuXJWoodcockEA, et al.Reduced phosphoinositide 3-kinase (p110α) activation increases the susceptibility to atrial fibrillation. Am J Pathol2009; 175: 998–1009.
67.
ThorpBCBadouxX. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management. Leuk Lymphoma2018; 59: 311–320.
68.
AsnaniAManningAMansourM, et al.Management of atrial fibrillation in patients taking targeted cancer therapies. Cardio-Oncology2017; 3. doi:10.1186/s40959-017-0021-y
69.
BrownJR. How i treat CLL patients with ibrutinib. Blood2018; 131: 379–386.
70.
BrownJRMoslehiJO’BrienS, et al.Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica2017; 102: 1796–1805.
71.
ThompsonPALévyVTamCS, et al.Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol2016; 175: 462–466.
72.
DickersonTWiczerTWallerA, et al.Hypertension and incident cardiovascular events following ibrutinib initiation. Blood2019; 134: 1919–1928.
73.
NatarajanGTerrazasCOghumuS, et al.Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells. Oncoimmunology2016; 5. doi:10.1080/2162402X.2015.1057385
74.
BurgerJABarrPMRobakT, et al.Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia2020; 34: 787–798.
75.
AhnIE. Cardiovascular adverse events of ibrutinib. Blood2019; 134: 1881–1882.
76.
LevadeMDavidEGarciaC, et al.Ibrutinib treatment affects collagen and von willebrand factor-dependent platelet functions. Blood2014; 124: 3991–3995.
77.
QuekLSBolenJWatsonSP. A role for Bruton's Tyrosine kinase (btk) in platelet activation by collagen. Curr Biol1998; 8: 1137–1140.
78.
KunkPRMockJDevittME, et al.Major bleeding with ibrutinib: more than expected. Blood2016; 128: 3229–3229.
79.
WhittleAMAllsupDJBaileyJR. Chronic lymphocytic leukaemia is a risk factor for venous thromboembolism. Leuk Res2011; 35: 419–421.
80.
WangMLRuleSMartinP, et al.Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med2013; 369: 507–516.
81.
ConnollySJEzekowitzMDYusufS, et al.Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med2009; 361: 1139–1151.
82.
GrangerCBAlexanderJHMcMurrayJJV, et al.Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med2011; 365: 981–992.
83.
PatelMRMahaffeyKWGargJ, et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med2011; 365: 883–891.
84.
GiuglianoRPRuffCTBraunwaldE, et al.Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med2013; 369: 2093–2104.
85.
RazMAArnasonJEBaireyO, et al.The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants. Blood2019; 134: 4314–4314.
86.
WangTFBaumann KreuzigerLLeaderA, et al.Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies—TacDOAC registry: communication from the ISTH SSC subcommittee on hemostasis and malignancy. J Thromb Haemost2021; 19: 2068–2081.
87.
LorenzRSpenglerUFischerS, et al.Platelet function, thromboxane formation and blood pressure control during supplementation of the western diet with cod liver oil. Circulation1983; 67: 504–511.
88.
PastoriDCarnevaleRCangemiR, et al.Vitamin E serum levels and bleeding risk in patients receiving oral anticoagulant therapy: a retrospective cohort study. J Am Heart Assoc2013; 2. doi:10.1161/JAHA.113.000364
89.
SrivastavaKC. Isolation and effects of some ginger components on platelet aggregation and eicosanoid biosynthesis. Prostaglandins. Leukot Med1986; 25: 187–198.
90.
RahmanK. Effects of garlic on platelet biochemistry and physiology. Mol Nutr Food Res2007; 51: 1335–1344.
91.
BrownJRHillmenPO’BrienS, et al.Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia2018; 32: 83–91.
92.
IberriDJKwongBYStevensLA, et al.Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management. Br J Haematol2018; 180: 164–166.
93.
StephensDMByrdJC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood2019; 133: 1298–1307.
94.
FiorcariSMaffeiRValleriniD, et al.BTK Inhibition impairs the innate response against fungal infection in patients with chronic lymphocytic leukemia. Front Immunol2020; 11. doi:10.3389/fimmu.2020.02158
95.
SunCTianXLeeYS, et al.Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood2015; 126: 2213–2219.
96.
YinQSivinaMRobinsH, et al.Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia. J Immunol2017; 198: 1740–1747.
AhnIEJerussiTFarooquiM, et al.Atypical pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood2016; 128: 1940–1943.
BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia.; July 29, 2021. Available at: https://www.businesswire.c.
101.
WeedaERColemanCIMcHorneyCA, et al.Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medications: a metaregression analysis. Int J Cardiol2016; 216: 104–109.
102.
LaliberteFBookhartBKNelsonWW, et al.Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient2013; 6: 213–224.
103.
SouersAJLeversonJDBoghaertER, et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med2013; 19: 202–208.
104.
StilgenbauerSEichhorstBScheteligJ, et al.Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol2016; 17: 768–778.
105.
SeymourJFKippsTJEichhorstB, et al.Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med2018; 378: 1107–1120.
106.
KaterAPSeymourJFHillmenP, et al.Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the murano phase III study. J Clin Oncol2019; 37: 269–277.
107.
FischerKAl-SawafOBahloJ, et al.Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med2019; 380: 2225–2236.
108.
Al-SawafOZhangCTandonM, et al.Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol2020; 21: 1188–1200.
109.
RobertsAWMaSKippsTJ, et al.Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood2019; 134: 111–122.
110.
BlomberyPAndersonMAGongJN, et al.Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov2019; 9: 342–353.
111.
TauschECloseWDolnikA, et al.Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica2019; 104: E434–E437.
112.
SeymourJFWuJQPopovicR, et al.Assessment of the clonal dynamics of acquired mutations in patients (Pts) with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) treated in the randomized phase 3 murano trial supports venetoclax-rituximab (VenR) fixed-duration combination treatment (Tx). Blood2021; 138: 1548–1548.
113.
MatoARThompsonMAllanJN, et al.Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica2018; 103: 1511–1517.
114.
RoekerLEFoxCPEyreTA, et al.Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice. Clin Cancer Res2019; 25: 4264–4270.
115.
KoenigKLHuangYDotsonEK, et al.Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists. Blood Adv2020; 4: 4860–4863.
116.
DavidsMSShadmanMParikhSA, et al.A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia. Blood2020; 136: 51–52.
117.
LiuLPuriKDPenningerJM, et al.Leukocyte PI3Kγ and PI3Kδ have temporally distinct roles for leukocyte recruitment in vivo. Blood2007; 110: 1191–1198.
118.
BarrientosJC. Idelalisib for the treatment of indolent non-hodgkin lymphoma: a review of its clinical potential. Onco Targets Ther2016; 9: 2945–2953.
119.
Ortiz MaldonadoVGarcia MorilloMDelgadoJ. The biology behind PI3 K inhibition in chronic lymphocytic leukaemia. Ther Adv Hematol2015; 6: 25–36.
120.
FurmanRRSharmanJPCoutreSE, et al.Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med2014; 370: 997–1007.
121.
JonesJARobakTBrownJR, et al.Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol2017; 4: e114–e126.
ShahABarrientosJC. Oral pi3k-δ,γ inhibitor for the management of people with chronic lymphocytic leukemia and small lymphocytic lymphoma: a narrative review on duvelisib. Onco Targets Ther2021; 14: 2109–2119.
124.
FlinnIWHillmenPMontilloM, et al.The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood2018; 132: 2446–2455.
125.
KienleDLStilgenbauerS. Approved and emerging PI3 K inhibitors for the treatment of chronic lymphocytic leukemia and non-hodgkin lymphoma. Expert Opin Pharmacother2020; 21: 917–929.
126.
DavidsMSKussBJHillmenP, et al.Efficacy and safety of duvelisib following disease progression on ofatumumab in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study. Clin Cancer Res2020; 26: 2096–2103.
127.
CoutréSEBarrientosJCBrownJR, et al.Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma2015; 56: 2779–2786.
128.
CuneoABarosiGDanesiR, et al.Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: a multidisciplinary position paper. Hematol Oncol2019; 37: 3–14.
129.
RhodesJMatoASharmanJP. Monitoring and management of toxicities of novel B cell signaling agents. Curr Oncol Rep2018; 20. doi:10.1007/s11912-018-0694-x
130.
HaustraeteEObertJDiabS, et al.Idelalisib-related pneumonitis. Eur Respir J.2016; 47: 1280–1283.
131.
EichhorstBFinkAMBahloJ, et al.First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol2016; 17: 928–942.
132.
HallekMFischerKFingerle-RowsonG, et al.Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet2010; 376: 1164–1174.
133.
AllanJNShanafeltTWiestnerA, et al.Long-Term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukemia (CLL) with 4 years of follow-up in patients with TP53 aberrations (del(17p) or TP53 mutation): a pooled analysis from 4 clinical trials. Blood2020; 136: 23–24.
134.
HarrupRAOwenCD’RozarioJ, et al.Efficacy of subsequent novel targeted therapies, including repeated venetoclax-rituximab (VenR), in patients (Pts) with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) previously treated with fixed-duration venr in the murano study. Blood2020; 136: 44–45.
135.
ThompsonMCAllanJNSailK, et al.Venetoclax Re-treatment of chronic lymphocytic leukemia (CLL) patients after a previous venetoclax-based regimen. Blood2020; 136: 39–41.
136.
RogersKAThompsonPAAllanJN, et al.Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica2021; 106: 2364–2373.
137.
AwanFTSchuhABrownJR, et al.Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv2019; 3: 1553–1562.
138.
ShadmanMSharmanJPLevyMY, et al.Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib. J Clin Oncol2021; 39: e19506–e19506.
139.
MatoARGhoshNSchusterSJ, et al.Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy. Blood2021; 137: 2817–2826.
140.
MatoARShahNNJurczakW, et al.Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet2021; 397: 892–901.
141.
BrownJRDavidsMSChangJE, et al.Outcomes of ibrutinib (ibr) therapy in ibr-naïve patients (pts) with chronic lymphocytic leukemia (CLL) progressing after venetoclax (ven). Blood2019; 134: 4320–4320.
142.
LinVSLewTEHandunnettiSM, et al.BTK Inhibitor therapy is effective in patients with CLL resistant to venetoclax. Blood2020; 135: 2266–2270.
143.
MatoARRoekerLEJacobsR, et al.Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy. Clin Cancer Res2020; 26: 3589–3596.
144.
JonesJAMatoARWierdaWG, et al.Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol2018; 19: 65–75.
145.
WierdaWGByrdJCDavidsMS, et al.Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor. Br J Haematol2019; 185: 961–966.
146.
EyreTAKirkwoodAAGohillS, et al.Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis. Br J Haematol2019; 185: 656–669.
147.
InnocentiIMorelliFAutoreF, et al.Venetoclax in CLL patients who progress after B-cell receptor inhibitor treatment: a retrospective multi-centre Italian experience. Br J Haematol2019; 187: e8–e11.
148.
HallekMChesonBDCatovskyD, et al.iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood2018; 131: 2745–2760.
149.
BöttcherSRitgenMFischerK, et al.Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol2012; 30: 980–988.
150.
KovacsGRobrechtSFinkAM, et al.Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL study group. J Clin Oncol2016; 34: 3758–3765.
151.
KwokMRawstronACVargheseA, et al.Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood2016; 128: 2770–2773.
152.
DimierNDelmarPWardC, et al.A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood2018; 131: 955–962.
153.
GuarenteVSportolettiP. Lessons, challenges and future therapeutic opportunities for pi3k inhibition in cll. Cancers (Basel)2021; 13: 1–15.
154.
BurrisHAFlinnIWPatelMR, et al.Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol2018; 19: 486–496.
155.
BarrPM. Umbralisib plus ublituximab is superior to obinutuzumab plus chlorambucil in patients with treatment-naive and relapsed/refractory chronic lymphocytic leukemia: results from the phase 3 unity-cll study. Clin Adv Hematol Oncol2021; 19: –9.
156.
WoyachJAFurmanRRLiuT-M, et al.Resistance mechanisms for the Bruton's Tyrosine kinase inhibitor ibrutinib. N Engl J Med2014; 370: 2286–2294.
157.
BrandhuberBGomezESmithS, et al.LOXO-305, A next generation reversible BTK inhibitor, for overcoming acquired resistance to irreversible BTK inhibitors. Clin Lymphoma Myeloma Leuk2018; 18: S216.
158.
WangEMiXThompsonMC, et al.Mechanisms of resistance to noncovalent Bruton's Tyrosine kinase inhibitors. N Engl J Med2022; 386: 735–743.
159.
Cervantes-GomezFLamotheBWoyachJA, et al.Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res2015; 21: 3705–3715.
160.
TahirSKSmithMLHesslerP, et al.Potential mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer2017; 17. doi:10.1186/s12885-017-3383-5
161.
JainNKeatingMThompsonP, et al.Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med2019; 380: 2095–2103.
162.
JainNKeatingMThompsonP, et al.Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial. JAMA Oncol2021; 7: 1213–1219.
163.
WierdaWGAllanJNSiddiqiT, et al.Ibrutinib Plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol. doi:10.1200/jco.21.00807. Published online 2021.
164.
TamCSAllanJNSiddiqiT, et al.Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. doi:10.1182/blood.2021014488. Published online 2022.
165.
MunirTMorenoCOwenC, et al.First prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib Plus venetoclax (ibr + ven) versus chlorambucil Plus obinutuzumab (clb + O) for first-line treatment of CLL in elderly or unfit patients: the glow study. Blood2021; 138: 70–70.
166.
RogersKAHuangYRuppertAS, et al.Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naïve and relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol2020; 38: 3626–3637.
167.
KerstingSLevinM-DNiemannCU, et al.First line treatment with venetoclax and ibrutinib induction followed by obinutuzumab intensification exclusively in CLL/SLL patients not in complete remission and/or with detectable bone marrow minimal residual disease (NEXT STEP trial). Blood2019; 134: 1753–1753.
168.
SoumeriJMatoARDoganPA. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Lancet2021; 8: E879–E890.
169.
GhiaPAllanJNSiddiqiT, et al.Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of the FD cohort of the phase 2 captivate study. J Clin Oncol2021; 39: 7501–7501.
